Corbus Pharmaceuticals Holdings, Inc. Repayments of Other Long-term Debt
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Repayments of Other Long-term Debt of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfOtherLongTermDebt · last filed 2026-03-09
- Corbus Pharmaceuticals Holdings, Inc. repayments of other long-term debt for the quarter ending 2025-12-31 was $0.00.
- Corbus Pharmaceuticals Holdings, Inc. repayments of other long-term debt for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. repayments of other long-term debt for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. repayments of other long-term debt for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. repayments of other long-term debt for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Corbus Pharmaceuticals Holdings, Inc. repayments of other long-term debt for fiscal 2024 was $15.18M, a 438.07% increase from fiscal 2023.
- Corbus Pharmaceuticals Holdings, Inc. repayments of other long-term debt for fiscal 2023 was $2.82M, a 87.98% increase from fiscal 2022.
- Corbus Pharmaceuticals Holdings, Inc. repayments of other long-term debt for fiscal 2022 was $1.50M.
| Period end | Repayments of Other Long-term Debt 3 month | Repayments of Other Long-term Debt 3 month as first filed | Repayments of Other Long-term Debt 6 month | Repayments of Other Long-term Debt 9 month | Repayments of Other Long-term Debt 9 month as first filed | Repayments of Other Long-term Debt 12 month | Repayments of Other Long-term Debt 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $0.00 derived: sum of 2 quarters · filed 2026-03-09 | $0.00 derived: sum of 3 quarters · filed 2026-03-09 | $0.00 10-K · filed 2026-03-09 | |||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 4 quarters · filed 2026-03-09 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $0.00 10-Q · filed 2025-08-05 | $0.00 derived: sum of 3 quarters · filed 2026-03-09 | $10.82M derived: sum of 4 quarters · filed 2026-03-09 | |||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-03-09 | $10.82M derived: sum of 3 quarters · filed 2026-03-09 | $12.97M derived: sum of 4 quarters · filed 2026-03-09 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $10.82M derived: sum of 2 quarters · filed 2026-03-09 | $12.97M derived: sum of 3 quarters · filed 2026-03-09 | $15.18M 10-K · filed 2026-03-09 | |||
| 2024-09-30 | $10.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $12.97M derived: sum of 2 quarters · filed 2025-11-12 | $15.18M 10-Q · filed 2025-11-12 | $17.31M derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2024-06-30 | $2.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $4.36M 10-Q · filed 2025-08-05 | $6.49M derived: sum of 3 quarters · filed 2025-08-05 | $7.18M derived: sum of 4 quarters · filed 2025-08-05 | |||
| 2024-03-31 | $2.21M 10-Q · filed 2025-05-06 | $2.21M 10-Q · filed 2024-05-07 | $4.34M derived: sum of 2 quarters · filed 2025-05-06 | $5.03M derived: sum of 3 quarters · filed 2025-05-06 | $5.03M derived: sum of 4 quarters · filed 2025-05-06 | ||
| 2023-12-31 | $2.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $2.82M derived: sum of 2 quarters · filed 2025-03-11 | $2.82M derived: sum of 3 quarters · filed 2025-03-11 | $2.82M 10-K · filed 2025-03-11 | $2.82M 10-K · filed 2024-03-12 | ||
| 2023-09-30 | $690.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $690.00K derived: sum of 2 quarters · filed 2024-11-07 | $690.00K 10-Q · filed 2024-11-07 | $689.54K 10-Q · filed 2023-11-07 | $2.19M derived: sum of 4 quarters · filed 2024-11-07 | ||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | $1.50M derived: sum of 3 quarters · filed 2024-08-06 | ||||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-07 | $1.50M derived: sum of 2 quarters · filed 2024-05-07 | |||||
| 2022-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $1.50M 10-K · filed 2024-03-12 | |||||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |